Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

NEW YORK and MAINZ, GERMANY, November 4, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (BNTX) (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust ...

Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; ...

Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were "substantially higher" in people who got its new bivalent booster compared with people who received ...

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA ...

Pfizer and BioNTech have submitted a request to the FDA for Emergency Use Authorization of an omicron-adapted COVID-19 booster dose for individuals 12 years of age and older. Pending authorization, ...

American pharmaceutical company Pfizer and its German partner BioNTech announced Friday that a booster dose of their bivalent COVID-19 vaccine performs better against two circulating versions of the ...

Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies said in a ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Trenae Nuri: Here's your Midday Brief for Tuesday, November 30th. I'm Trenae Nuri ...

BioNTech is the Marketing Authorization Holder for COMIRNATY ® and its adapted vaccines (COMIRNATY ® Original/Omicron BA.4-5; COMIRNATY ® Omicron XBB.1.5) in the United States, the European Union, the ...

Pfizer and BioNTech have also filed an application with the U.S. Food and Drug Administration (FDA) requesting approval of their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 ...